Today MassVentures published a blog post highlighting the impact in biomedical science of the early stage companies they’re supporting this year with Stage 1 and Stage 2 grants. Such grants are especially valuable to life science and deep tech startups, since the investments of time and capital take longer to realize impacts due to the inherent complexity of the technologies and how they’re used.
A member of Massachusetts’ world-renowned life sciences innovation ecosystem, MassVentures plays an important role helping new companies bridge the gap between research and commercialization.
In this post, MassVentures highlights the startups its supporting with new technologies in life sciences, including PlenOptika. Read the full story at MassVentures